Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inferring the diurnal variability of OH radical concentrations over the Amazon from BVOC measurements.
Ringsdorf A, Edtbauer A, Vilà-Guerau de Arellano J, Pfannerstill EY, Gromov S, Kumar V, Pozzer A, Wolff S, Tsokankunku A, Soergel M, Sá MO, Araújo A, Ditas F, Poehlker C, Lelieveld J, Williams J. Ringsdorf A, et al. Among authors: soergel m. Sci Rep. 2023 Sep 9;13(1):14900. doi: 10.1038/s41598-023-41748-4. Sci Rep. 2023. PMID: 37689759 Free PMC article.
Ensovibep, a SARS-CoV-2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first-in-human, ascending single-dose Phase 1 study.
Stojcheva N, Gladman S, Soergel M, Zitt C, Drake R, Lockett T, Marchand C, Fustier P, Stavropoulou V, Fernandez E, Pettigiani NL, Watkins K, Puri A, Watson R, Legenne P, Stumpp MT, Boyce M. Stojcheva N, et al. Among authors: soergel m. Br J Clin Pharmacol. 2023 Jul;89(7):2295-2303. doi: 10.1111/bcp.15747. Epub 2023 May 8. Br J Clin Pharmacol. 2023. PMID: 37057679 Clinical Trial.
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study.
Prins MLM, van der Plas JL, Vissers MFJM, Berends CL, Tresch G, Soergel M, Fernández E, van den Berge N, Duijsings D, Zitt C, Stavropoulou V, Zimmermann M, Drake RF, Burggraaf J, Groeneveld GH, Kamerling IMC. Prins MLM, et al. Among authors: soergel m. Br J Clin Pharmacol. 2023 Mar;89(3):1105-1114. doi: 10.1111/bcp.15560. Epub 2022 Oct 24. Br J Clin Pharmacol. 2023. PMID: 36214216 Free PMC article. Clinical Trial.
Low 1-year cyclosporine microemulsion doses are associated with better 5-year renal graft function: an insight from MOST, a multinational observational study.
Salvadori M, Rosati A, Bertoni E, Bock A, Chapman J, Dussol B, Fritsche L, Kliem V, Lebranchu Y, Oppenheimer F, Pohanka E, Tufveson G, Soergel M. Salvadori M, et al. Among authors: soergel m. Transplant Proc. 2006 May;38(4):1010-3. doi: 10.1016/j.transproceed.2006.03.060. Transplant Proc. 2006. PMID: 16757247
Delayed graft function: risk factors, consequences and parameters affecting outcome-results from MOST, A Multinational Observational Study.
Lebranchu Y, Halimi JM, Bock A, Chapman J, Dussol B, Fritsche L, Kliem V, Oppenheimer F, Pohanka E, Salvadori M, Soergel M, Tufveson G; MOST International Study Group. Lebranchu Y, et al. Among authors: soergel m. Transplant Proc. 2005 Jan-Feb;37(1):345-7. doi: 10.1016/j.transproceed.2004.12.297. Transplant Proc. 2005. PMID: 15808638
50 results